A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
166actual
Sites
29
Countries
Saudi Arabia, United Arab Emirates
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-11 | actual | When the study began enrolling |
| Primary completion | 2026-04-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-15 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Intervention
- Drug: Tirzepatide — also filed as LY3298176
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Hemoglobin A1c (HbA1c)
measured Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from Start of Ramadan (SoR)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed